Visit [ Ссылка ] for more.
Dr Moskowitz (Memorial Sloan Kettering Cancer Center, New York, USA) talks to ecancertv at ASH 2014 about the findings of a phase III trial which compared brentuximab vedotin (BV), an antibody targeting the CD30 protein on Hodgkin lymphoma cells, with placebo in 327 patients at risk of post-transplant disease progression.
